PBLS
+$0
407,132 sh
Flynn James E
10% Owner, Director · SEC CIK 1352546
Insider at
PBLS Parabilis Medicines, Inc.
LRMR Larimar Therapeutics, Inc.
NUVL Nuvalent, Inc.
SPRY ARS Pharmaceuticals, Inc.
PHGE BiomX Inc.
AFIB Acutus Medical, Inc.
BCAX Bicara Therapeutics Inc.
AHCO AdaptHealth Corp.
GUTS Fractyl Health, Inc.
CMAX CareMax, Inc.
DALS DA32 Life Science Tech Acquisition Corp.
ONCR Oncorus, Inc.
MIRM Mirum Pharmaceuticals, Inc.
Advertisement
Buy track record
How this insider's open-market purchases have performed42%
of buys now in profit
5 up · 7 down
Avg return since buy+2.2%
Median return−27.3%
Best trade+321.2%
Worst trade−72.8%
Buys scored12
Average return by holding period — separates good entry timing from riding one long winner
After 1 month
−8.5%
42% won · 12 trades
After 3 months
−14.3%
42% won · 12 trades
After 6 months
−2.2%
63% won · 8 trades
After 12 months
−17.4%
40% won · 5 trades
| Date | Company | 90d trend | Buy price | Value | ΔOwn | 1M | 3M | 6M | 12M | To date |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | LRMR | $5 | $5.42M | +11% | −13.0% | −33.7% | — | — | −34.7% | |
| Feb 27, 2026 | LRMR | $5 | $5.42M | +11% | −13.0% | −33.7% | — | — | −34.7% | |
| Feb 27, 2026 | LRMR | $5 | $4.16M | +11% | −13.0% | −33.7% | — | — | −34.7% | |
| Feb 27, 2026 | LRMR | $5 | $10M | +48% | −13.0% | −33.7% | — | — | −34.7% | |
| Jul 31, 2025 | LRMR | $3 | $10.84M | +55% | +7.2% | +12.4% | +1.4% | — | +0.3% | |
| Jul 31, 2025 | LRMR | $3 | $10.84M | +55% | +7.2% | +12.4% | +1.4% | — | +0.3% | |
| Jul 31, 2025 | LRMR | $3 | $8.32M | +55% | +7.2% | +12.4% | +1.4% | — | +0.3% | |
| Sep 17, 2024 | BCAX | $18 | $630K | +4.1% | −24.5% | −33.0% | −50.1% | −59.5% | −19.9% | |
| Feb 16, 2024 | LRMR | $9 | $12.5M | +30% | −34.7% | −41.9% | −40.6% | −74.3% | −72.8% | |
| Feb 16, 2024 | LRMR | $9 | $12.5M | +51% | −34.7% | −41.9% | −40.6% | −74.3% | −72.8% | |
| Nov 3, 2022 | NUVL | $34 | $21.78M | NEW | +16.7% | +2.8% | +26.9% | +92.6% | +321.2% | |
| Sep 16, 2022 | LRMR | $3 | $8.75M | NEW | +5.6% | +40.0% | +82.8% | +28.8% | +8.4% |
How this is calculated. We score only open-market purchases (SEC code
P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 12 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$111.15M
12 trades
Open-market sells
$157.09M
43 trades
Net flow
−$45.93M
Net selling
Total filings
67
transactions shown
Full transaction history
All Form 4 activity across every company, newest firstLRMR
Flynn James E, LRMR's 10% owner, spent $5.42M of their own money on 1.08M shares at $5, growing their stake 11%.
+$5.42M
1.08M sh @ $5
LRMR
Flynn James E, LRMR's 10% owner, spent $5.42M of their own money on 1.08M shares at $5, growing their stake 11%.
+$5.42M
1.08M sh @ $5
LRMR
Flynn James E, LRMR's 10% owner, spent $4.16M of their own money on 831,978 shares at $5, growing their stake 11%.
+$4.16M
831,978 sh @ $5
LRMR
Flynn James E, LRMR's 10% owner, spent $10M of their own money on 2M shares at $5, growing their stake 48%.
+$10M
2M sh @ $5
Advertisement
NUVL
−$35.44M
371,287 sh @ $95
LRMR
Flynn James E, LRMR's 10% owner, spent $10.84M of their own money on 3.39M shares at $3, growing their stake 55%.
+$10.84M
3.39M sh @ $3
LRMR
Flynn James E, LRMR's 10% owner, spent $10.84M of their own money on 3.39M shares at $3, growing their stake 55%.
+$10.84M
3.39M sh @ $3
LRMR
Flynn James E, LRMR's 10% owner, spent $8.32M of their own money on 2.6M shares at $3, growing their stake 55%.
+$8.32M
2.6M sh @ $3
SPRY
−$6.83M
370,075 sh @ $18
SPRY
−$6.83M
370,074 sh @ $18
NUVL
+$0
2,647 sh
PHGE
+$328.7K
353,249 sh @ $1
SPRY
−$134.8K
7,853 sh @ $17
SPRY
−$134.8K
7,854 sh @ $17
SPRY
−$169.8K
9,554 sh @ $18
SPRY
−$169.8K
9,553 sh @ $18
SPRY
−$708.4K
40,596 sh @ $17
SPRY
−$4.06M
223,632 sh @ $18
NUVL
−$97.75M
1M sh @ $98
BCAX
+$0
862,587 sh
BCAX
Flynn James E, BCAX's 10% owner, spent $630K of their own money on 35,000 shares at $18, growing their stake 4%.
+$630K
35,000 sh @ $18
PHGE
+$0
5.88M sh
NUVL
+$0
2,499 sh
PHGE
+$0
3.06M sh
AHCO
−$1.23M
114,906 sh @ $11
AHCO
−$1.03M
94,567 sh @ $11
AHCO
−$979.9K
88,040 sh @ $11
AHCO
−$524.1K
47,992 sh @ $11
AHCO
−$49.6K
4,495 sh @ $11
Frequently asked questions
How is Flynn James E's win rate calculated?
We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.
Why are some buys not included in the score?
A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.
What do the 1M / 3M / 6M / 12M columns mean?
They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.
Does a high win rate mean I should copy this insider?
No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.
Where does this data come from?
Trades come from Flynn James E's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.